Exploring TeraWulf And Two Other High Growth Tech Stocks

In This Article:

The market is up 1.2% over the last week and has risen 30% over the past 12 months, with earnings forecast to grow by 15% annually. In this favorable environment, identifying high-growth tech stocks like TeraWulf can be crucial for investors looking to capitalize on robust market conditions and promising future earnings potential.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

20.81%

27.98%

★★★★★★

TG Therapeutics

28.39%

43.54%

★★★★★★

Sarepta Therapeutics

23.58%

44.12%

★★★★★★

Invivyd

42.91%

70.39%

★★★★★★

Ardelyx

27.46%

66.34%

★★★★★★

Amicus Therapeutics

20.32%

62.37%

★★★★★★

Clene

71.89%

60.05%

★★★★★★

Travere Therapeutics

26.68%

68.80%

★★★★★★

Seagen

22.57%

71.80%

★★★★★★

ImmunoGen

26.00%

45.85%

★★★★★★

Click here to see the full list of 251 stocks from our US High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

TeraWulf

Simply Wall St Growth Rating: ★★★★★☆

Overview: TeraWulf Inc., along with its subsidiaries, operates as a digital asset technology company in the United States and has a market cap of $1.72 billion.

Operations: The company generates revenue primarily through digital currency mining, with a reported revenue of $120.25 million. The market capitalization stands at approximately $1.72 billion.

TeraWulf, amidst a volatile market, is navigating through its unprofitability with strategic maneuvers aimed at robust future growth. With an impressive revenue forecast growing at 53.1% annually, it outpaces the broader US market's 8.7% growth expectation. This surge is underpinned by significant R&D investment, crucial for staying competitive in tech-intensive sectors like AI and high-performance computing. Recent operational highlights include mining 184 bitcoins in August alone while efficiently managing production costs despite challenging economic conditions. Moreover, their proactive financial strategies are evident from the recent auditor change to Deloitte and full repayment of their term loan, positioning them for sustainable expansion and potentially profitable years ahead as forecasted earnings growth hits a remarkable 108.6% annually.

NasdaqCM:WULF Revenue and Expenses Breakdown as at Sep 2024

Sarepta Therapeutics

Simply Wall St Growth Rating: ★★★★★★

Overview: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for rare diseases, with a market cap of $12.13 billion.